These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 23647298)
1. Rare mutations in non-small-cell lung cancer. D'Arcangelo M; D'Incecco A; Cappuzzo F Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298 [TBL] [Abstract][Full Text] [Related]
2. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164 [TBL] [Abstract][Full Text] [Related]
3. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168 [TBL] [Abstract][Full Text] [Related]
4. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients. Bhaumik S; Ahmad F; Das BR Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917 [TBL] [Abstract][Full Text] [Related]
5. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325 [TBL] [Abstract][Full Text] [Related]
6. HER2 and lung cancer. Landi L; Cappuzzo F Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423 [TBL] [Abstract][Full Text] [Related]
7. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121 [TBL] [Abstract][Full Text] [Related]
8. BRAF-mutations in non-small cell lung cancer. Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757 [TBL] [Abstract][Full Text] [Related]
9. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984 [TBL] [Abstract][Full Text] [Related]
10. New driver mutations in non-small-cell lung cancer. Pao W; Girard N Lancet Oncol; 2011 Feb; 12(2):175-80. PubMed ID: 21277552 [TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for NSCLC with driver mutations. Minuti G; D'Incecco A; Cappuzzo F Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339 [TBL] [Abstract][Full Text] [Related]
13. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Willmore-Payne C; Holden JA; Layfield LJ Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218 [TBL] [Abstract][Full Text] [Related]
14. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133 [TBL] [Abstract][Full Text] [Related]
15. [Which platform to support a personalized lung cancer treatment?]. Ruppert AM; Antoine M; Beau-Faller M; Cadranel J; Wislez M Bull Cancer; 2012 May; 99(5):529-34. PubMed ID: 22525302 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769 [TBL] [Abstract][Full Text] [Related]
17. Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality. Taus A; Vollmer I; Arriola E Arch Bronconeumol; 2011 Feb; 47(2):103-5. PubMed ID: 20678850 [TBL] [Abstract][Full Text] [Related]
18. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Alrifai D; Popat S; Ahmed M; Gonzalez D; Nicholson AG; Parcq Jd; Benepal T Lung Cancer; 2013 Jun; 80(3):339-40. PubMed ID: 23499398 [TBL] [Abstract][Full Text] [Related]
19. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594 [TBL] [Abstract][Full Text] [Related]
20. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]